Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection
Status:
Completed
Trial end date:
1997-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs like liposomal amphotericin B may be able to relieve fungal infection which
can be a side effect of chemotherapy. Colony-stimulating factors such as sargramostim may
increase the number of immune cells found in bone marrow or peripheral blood and may help a
person's immune system recover from the side effects of chemotherapy. It is not yet known
whether receiving liposomal amphotericin B plus sargramostim is more effective than receiving
liposomal amphotericin B alone in treating patients with invasive fungal infection.
PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of liposomal
amphotericin B with or without sargramostim in treating patients with invasive fungal
infection.
Phase:
Phase 3
Details
Lead Sponsor:
Medical Research Council
Treatments:
Amphotericin B Liposomal amphotericin B Sargramostim